US-based Avidity Biosciences Inc (Nasdaq: RNA), a biopharmaceutical company, has named Jae Kim MD as its new chief medical officer, it was reported on Monday.

In the new role, Dr Kim is to lead and expand the company's AOC range and will serve as a key member of its executive management team.

Prior to joining Avidity, Dr Kim was clinical research head, chair of the Clinical Trial Review Board, and vice president of Clinical Development at Alnylam Pharmaceuticals Inc. Dr.Kim has also held the roles of increasing responsibilities at MyoKardia Inc and Amgen, and served on the Faculty of Medicine at Harvard Medical School and the Brigham and Women's Hospital before joining industry.